Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347200 | 0.98 | CYP2D6 (0.37) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL1371388 | 0.81 | CA1 (0.56) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL8225915 | 0.79 | CYP2D6 (0.39) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL15503069 | 0.79 | CYP2D6 (0.56) | TSHRCYP2D6SMN1; SMN2CYP2C19CYP2C9 | |
| SCHEMBL29649359 | 0.78 | CA1 (0.52) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL346463 | 0.74 | CYP2D6 (0.39) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL346464 | 0.74 | TSHR (0.37) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL12256299 | 0.74 | CYP2D6 (0.36) | TSHRCYP2D6SMN1; SMN2CYP2C19ACLY | |
| SCHEMBL417152 | 0.73 | CA1 (0.58) | TSHRCYP2C19CYP2C9CYP3A4CA1 | |
| SCHEMBL3937944 | 0.73 | CA1 (0.58) | TSHRCYP2C19CYP2C9CYP3A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TSHR 4046/4885CYP2D6 644/4885SMN1; SMN2 3535/4885 |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TSHR 4046/4885CYP2D6 644/4885SMN1; SMN2 3535/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TSHR 4046/4885CYP2D6 644/4885SMN1; SMN2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.